T. Rowe Price Associates
SNDX icon

T. Rowe Price Associates’s Syndax Pharmaceuticals SNDX Stock Holding History

T. Rowe Price Associates’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.8M Buy
128,199
+21,066
+20% +$438K ﹤0.01% 1844
2026
Q1 		$2.5M Buy
107,133
+12,304
+13% +$267K ﹤0.01% 1728
2025
Q4 		$1.99M Buy
94,829
+3,695
+4% +$64.5K ﹤0.01% 1753
2025
Q3 		$1.4M Buy
91,134
+15,730
+21% +$206K ﹤0.01% 1901
2025
Q2 		$706K Buy
75,404
+9,290
+14% +$102K ﹤0.01% 2138
2025
Q1 		$813K Buy
66,114
+9,095
+16% +$128K ﹤0.01% 2056
2024
Q4 		$754K Buy
57,019
+8,092
+17% +$138K ﹤0.01% 2097
2024
Q3 		$942K Buy
48,927
+729
+2% +$15.1K ﹤0.01% 1997
2024
Q2 		$990K Buy
48,198
+3,688
+8% +$77.2K ﹤0.01% 1899
2024
Q1 		$1.06M Buy
44,510
+18,243
+69% +$407K ﹤0.01% 1892
2023
Q4 		$568K Buy
26,267
+1,857
+8% +$28.5K ﹤0.01% 2123
2023
Q3 		$355K Buy
24,410
+1,471
+6% +$27.8K ﹤0.01% 2273
2023
Q2 		$481K Buy
22,939
+11,575
+102% +$241K ﹤0.01% 2151
2023
Q1 		$241K Buy
11,364
+2,000
+21% +$49.8K ﹤0.01% 2445
2022
Q4 		$238K Buy
9,364
+935
+11% +$21.8K ﹤0.01% 2464
2022
Q3 		$203K Buy
+8,429
New +$189K ﹤0.01% 2538
2021
Q4 		– Sell
-516,098
Closed -$9.86M – 3035
2021
Q3 		$9.86M Buy
516,098
+95,678
+23% +$1.59M ﹤0.01% 1419
2021
Q2 		$7.22M Sell
420,420
-18,597
-4% -$341K ﹤0.01% 1456
2021
Q1 		$9.82M Buy
439,017
+267,578
+156% +$6.05M ﹤0.01% 1397
2020
Q4 		$3.81M Buy
+171,439
New +$3.56M ﹤0.01% 1479

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

T. Rowe Price Associates's SNDX Position: Q2 2026 in Review

T. Rowe Price Associates increased its Syndax Pharmaceuticals (SNDX) stake by 20% in Q2 2026, buying an estimated $438K and bringing the position to 128,199 shares worth $2.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1844.

T. Rowe Price Associates first reported a position in SNDX in Q4 2020 and has held it in 20 quarters since. The position peaked at $9.86M in Q3 2021. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • T. Rowe Price Associates held 128,199 shares of Syndax Pharmaceuticals worth $2.8M as of Q2 2026.
  • T. Rowe Price Associates bought 21,066 Syndax Pharmaceuticals shares in Q2 2026, an estimated $438K.
  • Syndax Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1844 holding.
  • T. Rowe Price Associates first reported a position in Syndax Pharmaceuticals in Q4 2020 and has held it in 20 quarters since.
  • T. Rowe Price Associates's Syndax Pharmaceuticals position peaked at $9.86M in Q3 2021.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.